Worcester HIV Vaccine

News

WHV Prepares to File Investigational New Drug (IND) Application to the U.S. FDA to Test its Candidate HIV Vaccine in a Phase IIa Clinical Trial

WHV is preparing to file a new IND for PDPHV, its investigational DNA-prime/protein-boost vaccine.  PDPHV is comprised of five DNA plasmids and four gp120 recombinant proteins and is being tested in a Phase I clinical trial (HVTN 124) as a prime-boost regimen or co-administered in repeated doses, in healthy adult volunteers. Results of the HVTN 124 trial are expected in early/mid 2020.  If the vaccine is proven safe and immunogenic, the IND will allow WHV to rapidly advance PDPHV through to Phase IIa clinical testing.

The National Institutes of Allergy and Infectious Diseases (NIAID) holds the current IND for the vaccine candidate and NIAID-supported HVTN is running the Phase I HVTN 124 trial.  WHV will work with NIAID, the U.S. FDA, and other regulatory partners to clarify the regulatory pathway for PDPHV.

For more information on the HVTN124 trial, please visit HVTN 124 Trial.

WHV hires Dr. Yegor Voronin as its Chief Operating Officer

WHV hired Dr. Yegor Voronin to manage the day-to-day operation of the company and to develop the strategy for development of its PDPHV preventive HIV vaccine candidate. Dr. Voronin previously served as the Senior Science Officer at the Global HIV Vaccine Enterprise in New York. He brings over 15 years of HIV research and vaccine development expertise. Dr. Voronin holds a Ph.D. from the West Virginia University and did his postdoctoral fellow training in the laboratories of Dr. Michael Emerman and Dr. Julie Overbaugh at the Fred Hutchinson Cancer Research Center, Seattle.